Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study
Sponsor: 150th Hospital of PLA
Terminated
As there are so many clinical trials in progress and the number of patients enrolled limited.
Listed as NCT02621333, this PHASE2 trial focuses on Lung Adenocarcinoma and remains terminated or withdrawn. Sponsored by 150th Hospital of PLA, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2021 — Oct 2021 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Unknown Status PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Oct 2018 — Apr 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 150th Hospital of PLA
- Anyang Regional Hospital
- First Affiliated Hospital of Nanyang Medical College
- First People's Hospital of Shangqiu
- Hebei Medical University Fourth Hospital
- Henan Cancer Hospital
- Henan Provincial People's Hospital
- Jiaozuo Tumor Hospital
- Nanyang Central Hospital
- Puyang Oilfield General Hospital
- Shanxi Dayi Hospital
- Shenma Medical Group General Hospital
- Tangshan People's Hospital
- The 152th Central Hospital of PLA
- Xinyang Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .